ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1538

The Age At Onset Of Symptoms Influence The Clinical Expression Of The Disease In Patients With Ankylosing Spondylitis

Natalia Zamora1, Emilce Edith Schneeberger1, Luis Alejandro Cayetti2, Fernando Sommerfleck1 and Gustavo Citera1, 1Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS)

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: II

Session Type: Abstract Submissions (ACR)

Background/Purpose: The onset of symptoms before 10 years and after 40 years is uncommon in patients with ankylosing spondylitis (AS). Some authors have found specific characteristics in patients with late-onset AS. Objective: To evaluate demographic and clinical characteristics in patients with conventional and late onset AS. 

Methods: Consecutive patients with AS (ASAS 2009 criteria) were included. Age at onset of symptoms, demographic and clinical characteristics were recollected. Presence of comorbidities, as well as specific questionnaires to determine disease activity (BASDAI), functional capacity (BASFI), quality of life (ASQoL) and metrology (BASMI) were assessed. Cervical, lumbar and pelvic X-rays were performed yearly and read by a single, blinded observer, according to BASRI. Descriptive statistics was used, the study population was dichotomized into two age groups in terms of symptom’s onset: ≤ 40 years and > 40 years. Categorical variables were compared by Chi2 or Fisher exact test and continued variables by T test and ANOVA. Logistic regression analysis using the two age groups as dependent variable was performed to determine associations and to adjust for covariates.

Results:  A total of 147 patients were included, 111 (75.5%) were male, with a median age of 46 years (IQR 32-56), median age of onset of symptoms 25 years (IQR 16-23) and median disease duration of 16 years (IQR 8-25). 18 (12.2%) patients had associated psoriasis, 18 were juvenile onset AS, 8 had inflammatory bowel disease associated (IBD), 5 were undifferentiated and the rest 98 (66.7%) had pure AS. 127 (86.4%) of patients had started the disease ≤ 40 years and 20 (13.6%) > 40 years. The group of patients with late onset AS were most often women [11 (45%) vs 27 (21%)], and patients with early onset had longer disease duration 19.4 vs 11.4 yrs p=0.01. After adjusting for these variables, patients in group > 40 showed a higher frequency of psoriasis (45% vs 11.3%), higher disease activity  (BASDAI: 5.9 vs 4.4), worse functional capacity (BASFI:5.6 vs 4.1), and quality of life (ASQoL:11.4 vs. 7.2), but less radiological damage (BASRI:6.75 vs 9.27),  p values <0.05 for all comparisons.

Conclusion: Patients with late onset AS are more frequently women with psoriasis and have worse indices of disease activity, functional capacity and quality of life. The presence of less radiological damage in this group deserves further investigation.


Disclosure:

N. Zamora,
None;

E. E. Schneeberger,
None;

L. A. Cayetti,
None;

F. Sommerfleck,
None;

G. Citera,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-age-at-onset-of-symptoms-influence-the-clinical-expression-of-the-disease-in-patients-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology